score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6316	152.0	1.6e-05	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	1.0	4.0	0.0	0.161	BRAF p.V600E (Missense)	1	example	example_patient_tumor	example_patient_normal
Investigate Actionability - High	FDA-Approved	Guideline	Guideline	Microsatellite Stability	MSI-High								Investigate Actionability - High	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options.	Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf. Revised October 2020. Accessed November 4, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf	Investigate Actionability - High	5-Fluorouracil	Thymidylate synthase inhibition	Chemotherapy	Patients with MSI-High colorectal cancer appear not to benefit from, and may be resistant to, 5-fluorouracil therapy.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability - High	1	Patients with MSI-High colorectal cancer often have a favorable prognosis.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					MSI-High		example		
Investigate Actionability - High	Guideline			Rearrangement	COL1A1	Fusion	COL1A1--CITED4			0.0	0.0		Investigate Actionability - High	Imatinib	PDGF-R inhibition	Targeted therapy	Imatinib has shown clinical activity against localized and metastatic DFSP tumors containing t(17;22)(q22;q13).	National Comprehensive Cancer Network. Dermatofibrosarcoma NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf																	COL1A1--CITED4 Fusion	0	example		
Investigate Actionability - High	Preclinical			Copy Number	CDKN2A	Deletion				0.0	0.0		Investigate Actionability - High	EPZ015666	PRMT5 inhibition	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214																	CDKN2A Deletion		example		
Investigate Actionability - High		Clinical evidence		Copy Number	BRAF	Amplification				0.0	0.0									Investigate Actionability - High	Vemurafenib	B-RAF inhibition	Targeted therapy	Amplification of BRAF may predict resistance to RAF inhibition.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631						1.0				BRAF Amplification		example		
Investigate Actionability - High			Guideline	Copy Number	TP53	Deletion				0.0	0.0																Investigate Actionability - High	0	Deletion of 17p13 leads to LoH of TP53 and is considered a high-risk feature of multiple myeloma.	National Comprehensive Cancer Network. Multiple Myeloma NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf	1.0				TP53 Deletion		example		
Investigate Actionability - High			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability - High	0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1							example		
Investigate Actionability - Low	FDA-Approved			Germline Variant	BRCA2	Frameshift	p.S1982fs	0.5	100.0	0.0	0.0	Pathogenic	Investigate Actionability - Low	Talazoparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative localy advanced or metastatic breast cancer. 	Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211651s006lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211651s006lbl.pdf																	BRCA2 p.S1982fs (Frameshift)		example	__UNKNOWN__	example_normal_profile
Investigate Actionability - Low	Clinical evidence			Somatic Variant	MSH2	Missense	p.D887N	0.8039	51.0	0.0	0.0		Investigate Actionability - Low	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596														0.0	0.0	0.0	MSH2 p.D887N (Missense)		example	example_patient_tumor	example_patient_normal
Investigate Actionability - Low			Guideline	Somatic Variant	ZRSR2	Missense	p.N261I	0.4019	107.0	0.0	0.0																Investigate Actionability - Low	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf		29.0	0.0	0.9987	ZRSR2 p.N261I (Missense)		example	example_patient_tumor	example_patient_normal
Investigate Actionability - Low			Guideline	Somatic Variant	STAG2	Missense	p.F467I	0.3571	56.0	0.0	0.0																Investigate Actionability - Low	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf		27.0	0.0	0.9881	STAG2 p.F467I (Missense)		example	example_patient_tumor	example_patient_normal
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.G674E	0.4	40.0	0.0	0.0																						222.0	0.0	1.0	PDGFRB p.G674E (Missense)		example	example_patient_tumor	example_patient_normal
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.H300Y	0.6136	44.0	0.0	0.0																						17.0	0.0	0.9982	NTRK2 p.H300Y (Missense)		example	example_patient_tumor	example_patient_normal
Biologically Relevant				Germline Variant	BRAF	Nonsense	p.R509*	0.5	100.0	0.0	0.0																									BRAF p.R509* (Nonsense)		example	__UNKNOWN__	example_normal_profile
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.E282del (Deletion)																													Supporting variants: PRDM2 p.E282del (Deletion)		example		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.645																													COSMIC Signature (version 2) 7 (64%)		example		
